The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. P...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacogenomics J
Hlavní autoři: Feng, QiPing, Wei, Wei-Qi, Chung, Cecilia P, Levinson, Rebecca T, Bastarache, Lisa, Denny, Joshua C., Stein, C Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4995153/
https://ncbi.nlm.nih.gov/pubmed/26902539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2016.3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky